In recent decades, much attention has been focused on applying mesenchymal stem cells (MSCs) in biomedicine due to their property to be hypoimmunogenic or ‘immune privileged’, which enable them to bypass the major histocompatibility barriers. What’s more, MSCs have the ability to regulate the activation, proliferation, and function of several subsets of immune cells, including both innate and adaptive compartments. It is also widely known that MSCs possess broad immunoregulatory properties that could be applied in the therapeutic process for several diseases such as arthritis, graft versus host disease, fibrosis, systemic lupus erythematosus, etc.
The immune system plays an important role in the pathogenesis of gastrointestinal/hepatic diseases. There has been a sharp rise in the number of preclinical and clinical trials that use MSCs to treat gastrointestinal/hepatic diseases, including acute-on-chronic liver failure (ACLF), liver failure cirrhosis, primary biliary cholangitis, and inflammatory bowel disease (especially Crohn’s disease). The immune system is educated to maintain a balanced state because of the intestinal microbiome. Liver resident immune cells, such as kupffer cells and tissue resident memory cells (TRM), and other cells maintain hepatic homeostasis. When the immune system is out of balance, inflammation of the gastrointestinal/hepatic tract occurs, leading to diseases.
This Research Topic aims to bring together scientists working on gastrointestinal/hepatic diseases and immunomodulatory roles of MSCs in biomedicine, to uncover the immunomodulatory effects of MSCs in gastrointestinal/hepatic diseases. We welcome submissions of Original Research, Review, Mini Review, Hypothesis and Theory, focusing on, but not limited to, the following aspects:
• Screening of new molecules for the immunomodulation of gastrointestinal/hepatic diseases by MSCs.
• The mechanisms of the interaction between MSCs and immune system in gastrointestinal/hepatic diseases.
• Mesenchymal stem cell-derived exosomes for the immunomodulatory therapies of gastrointestinal/hepatic diseases.
In recent decades, much attention has been focused on applying mesenchymal stem cells (MSCs) in biomedicine due to their property to be hypoimmunogenic or ‘immune privileged’, which enable them to bypass the major histocompatibility barriers. What’s more, MSCs have the ability to regulate the activation, proliferation, and function of several subsets of immune cells, including both innate and adaptive compartments. It is also widely known that MSCs possess broad immunoregulatory properties that could be applied in the therapeutic process for several diseases such as arthritis, graft versus host disease, fibrosis, systemic lupus erythematosus, etc.
The immune system plays an important role in the pathogenesis of gastrointestinal/hepatic diseases. There has been a sharp rise in the number of preclinical and clinical trials that use MSCs to treat gastrointestinal/hepatic diseases, including acute-on-chronic liver failure (ACLF), liver failure cirrhosis, primary biliary cholangitis, and inflammatory bowel disease (especially Crohn’s disease). The immune system is educated to maintain a balanced state because of the intestinal microbiome. Liver resident immune cells, such as kupffer cells and tissue resident memory cells (TRM), and other cells maintain hepatic homeostasis. When the immune system is out of balance, inflammation of the gastrointestinal/hepatic tract occurs, leading to diseases.
This Research Topic aims to bring together scientists working on gastrointestinal/hepatic diseases and immunomodulatory roles of MSCs in biomedicine, to uncover the immunomodulatory effects of MSCs in gastrointestinal/hepatic diseases. We welcome submissions of Original Research, Review, Mini Review, Hypothesis and Theory, focusing on, but not limited to, the following aspects:
• Screening of new molecules for the immunomodulation of gastrointestinal/hepatic diseases by MSCs.
• The mechanisms of the interaction between MSCs and immune system in gastrointestinal/hepatic diseases.
• Mesenchymal stem cell-derived exosomes for the immunomodulatory therapies of gastrointestinal/hepatic diseases.
